Medullary Thyroid Cancer - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 105 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Medullary Thyroid Cancer - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Medullary Thyroid Cancer - Pipeline Review, H2 2014', provides an overview of the Medullary Thyroid Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Medullary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medullary Thyroid Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Medullary Thyroid Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Medullary Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Medullary Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Medullary Thyroid Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Medullary Thyroid Cancer - Overview 8
Pipeline Products for Medullary Thyroid Cancer - Comparative Analysis 9
Medullary Thyroid Cancer - Therapeutics under Development by Companies 10
Medullary Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 12
Medullary Thyroid Cancer - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Medullary Thyroid Cancer - Products under Development by Companies 16
Medullary Thyroid Cancer - Products under Investigation by Universities/Institutes 17
Medullary Thyroid Cancer - Companies Involved in Therapeutics Development 18
Boehringer Ingelheim GmbH 18
AstraZeneca PLC 19
Novartis AG 20
Immunomedics, Inc. 21
Ariad Pharmaceuticals, Inc. 22
Nerviano Medical Sciences 23
Advenchen Laboratories, LLC 24
Globeimmune, Inc. 25
Medullary Thyroid Cancer - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 30
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
vandetanib - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
vandetanib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
pasireotide - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ponatinib - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
everolimus - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
AL-3818 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
nintedanib - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
GI-6207 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
TF-2 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
CLM-29 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
NMS-616 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecules to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Small Molecules to Inhibit mTOR and RET Receptor Tyrosine Kinase for Oncology - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Medullary Thyroid Cancer - Recent Pipeline Updates 72
Medullary Thyroid Cancer - Dormant Projects 96
Medullary Thyroid Cancer - Product Development Milestones 97
Featured News & Press Releases 97
Mar 25, 2014: Cometriq approved in Europe for the treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma 97
Dec 19, 2013: COMETRIQ Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma 97
Jun 02, 2013: Exelixis Presents Cometriq Clinical Trial Data In Patients With Progressive, Metastatic Medullary Thyroid Cancer 98
May 07, 2013: Exelixis To Feature Nine Presentations On Cabozantinib At 2013 ASCO Annual Meeting 100
Apr 08, 2013: Ariad Pharma Presents New Preclinical Data On Ponatinib At AACR Annual Meeting 2013 101
Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer 102
Feb 14, 2013: Eisai's Thyroid Cancer Drug Candidate Lenvatinib Obtains FDA Orphan Drug Status 102
Jan 24, 2013: Exelixis's Cometriq Is Now Available In US 102
Dec 07, 2012: Catalent Pharma To Supply FDA Approved Exelixis's Cometriq In US Market 103
Nov 29, 2012: Exelixis Announces EMA Acceptance Of Marketing Authorization Application For Thyroid Cancer Drug Cometriq 103
Appendix 104
Methodology 104
Coverage 104
Secondary Research 104
Primary Research 104
Expert Panel Validation 104
Contact Us 105
Disclaimer 105

List of Tables
Number of Products under Development for Medullary Thyroid Cancer, H2 2014 8
Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Medullary Thyroid Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 18
Medullary Thyroid Cancer - Pipeline by AstraZeneca PLC, H2 2014 19
Medullary Thyroid Cancer - Pipeline by Novartis AG, H2 2014 20
Medullary Thyroid Cancer - Pipeline by Immunomedics, Inc., H2 2014 21
Medullary Thyroid Cancer - Pipeline by Ariad Pharmaceuticals, Inc., H2 2014 22
Medullary Thyroid Cancer - Pipeline by Nerviano Medical Sciences, H2 2014 23
Medullary Thyroid Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2014 24
Medullary Thyroid Cancer - Pipeline by Globeimmune, Inc., H2 2014 25
Assessment by Monotherapy Products, H2 2014 26
Number of Products by Stage and Target, H2 2014 29
Number of Products by Stage and Mechanism of Action, H2 2014 32
Number of Products by Stage and Route of Administration, H2 2014 34
Number of Products by Stage and Molecule Type, H2 2014 36
Medullary Thyroid Cancer Therapeutics - Recent Pipeline Updates, H2 2014 72
Medullary Thyroid Cancer - Dormant Projects, H2 2014 96